Evaluation of Ocoxin®-Viusid® in Breast Cancer

Phase 2

Completed

• Conditions: Breast Cancer; Adriamycin Toxicity; Breast Carcinoma; Cyclosporine Toxicity
• Interventions: Combination Product: CT + Ocoxin-Viusid; Combination Product: CT + Placebo

• Registration Number: NCT03576521
• Lead Sponsor: Catalysis SL

Brief Summary

The purpose is to determine the efficacy of the nutritional supplement Ocoxin-Viusid oral solution (OV) in the reduction of acute toxicity of Chemotherapy (CT) treatment with patients with breast carcinoma. A randomized, double-blind phase II clinical trial was designed, with a sample of 120 patients distributed in 2 arms: 60 patients will receive the CT treatment plus the OV, 60 will receive CT plus OV placebo. The OV / placebo will be administered before, during and 3 weeks after the conclusion of the CT. A better tolerance to the treatment is expected with the addition of the nutritional supplement.

Detailed Description

To obtain the sample size, the proportion of patients presenting adverse reactions that require interrupting chemotherapy treatment will be taken into account. In the institution, this figure is close to 15%. Since it is a dietary supplement, with extensive information on the safety of the product, the design is used in a stage of Flemming (without early stop rules). Assuming that the Ocoxin-Viusid product would clearly be declared ineffective (maximal ineffectiveness) if the proportion of patients not presenting adverse reactions was equal to less than 85% (p0), that is the maximum level of success below which the product does not shows signs of efficacy (the study does not guarantee further research) and taking a p1 value of 95%, where p1 is the minimum level of efficacy required from which the product would be declared effective (the results guarantee to continue a study phase III). Assuming an α error of 5% (probability of rejecting the null hypothesis when it is true) and β (probability of rejecting the alternative hypothesis when it is true) of 20% (the power of the test: 1 - β = 80%), It is determined to recruit a maximum number of 59 - 60 subjects. Determine a = 54, where a is the number of responses equal and below which the product is declared ineffective (H0 is accepted). And r = a + 1 is the cut-off point, that is, the number of responses from which the efficacy level ensures to continue to a phase III study. In this case we would expect to obtain a number of successes ≥ 55.

Patients will be randomized after surgery, in the chemotherapy consultation, and once they meet the established inclusion criteria. In order to achieve the masking of the research product, these have been labeled by a balanced randomized list obtained by computer, which will be in the possession of the Biostatistician of the study of the Clinical Investigations Section of INOR and the promoter. The product under study has been consecutively labeled from 1 to 120 (60 patients in each therapeutic arm).

Study Timeline

• Study Start: 2015-05-13
• Primary Completion: 2018-01-01
• Study Completion: 2018-02-19
• Status Verified: 2018-06
• Study First Submitted: 2018-06-13
• Study First Submitted QC: 2018-06-22
• Last Update Submitted: 2018-06-22
• Study First Posted: 2018-07-03
• Last Update Posted: 2018-07-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

1. Patients who have undergone surgery and histologically confirm a breast carcinoma and who are subject to adjuvant treatment with AC chemotherapy at the time of inclusion in the trial.

2. Patients with age ≥18 years of female sex.

3. General health status according to the Karnofsky Index ≥ 70.

4. Laboratory parameters within the normal limits defined to receive this chemotherapy including normal Echocardiogram:

   to. Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L.

   b. Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase.

   c. Renal function: creatinine ≤ 132 μmol / l.

5. Patients who express written voluntariness to enter the study with their signature of the informed consent document.

6. Patients of childbearing age with negative pregnancy test or who have effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation.

Exclusion Criteria

1. Patients who have received prior chemotherapy.
2. Patients who are receiving another research product.
3. Patients with known hypersensitivity to any ingredient of the investigational product.
4. Decompensated intercurrent diseases, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic diseases and psychiatric illnesses that could limit adherence to the requirements of the clinical trial or any other special condition that at the discretion of the physician put your health or life at risk during your participation in the trial.
5. Pregnancy, lactation or puerperium.
6. Patients with cerebral metastases and / or leptomeningeal carcinosis.
7. Patients with a second concomitant tumor.
8. Patients carrying the human immunodeficiency virus (HIV).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ocoxin-Viusid®	CT + Ocoxin-Viusid	The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
Placebo	CT + Placebo	The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.

Primary Outcome Measures

Name	Time	Method
The Ocoxin-Viusid effect in the treatment with chemotherapy	4 months	The effect of the treatment will be evaluated from the percentage of interruptions of oncospecific treatment due to acute toxic reactions to chemotherapy.
Compliance with the planned chemotherapy schedule	4 months	Dichotomous variable that will be evaluated through the answer yes or no. In cases of negative response, the cause of non-compliance will be collected. It will be collected in the evaluation corresponding to each cycle of chemotherapy and in the final evaluation.

Secondary Outcome Measures

Name	Time	Method
Evaluation of Quality of Life	4 months	It will be measured through quality of life scale of the EORTC QLQ-BR23 (specific for breast cancer), it contains 31-53 questions, with a scale from 1-4 or 1-7 (bad-excellent): -Functional scales: Body image (BRBI) Sexual functioning (BRSEF) Sexual enjoyment (BRSEE) Future perspective (BRFU); -Symptom scales / items; Systemic therapy side effects (BRST) Breast symptoms (BRBS) Arm symptoms (BRAS) Upset by hair loss (BRHL)
Evaluation of nutritional status	4 months	It will be determined through the value of total proteins and albumin.
Side effects of the treatment	4 months	The safety of the treatment will be determined through the reporting of adverse events that are presented to the research product.

Trial Locations

Locations (1)

National Institute of Oncology and Radiobiology (INOR); 🇨🇺 La Habana, Cuba